Combined Enhanced External Counterpulsation and Hyperbaric Oxygen Therapy in Ischemic Cardiomyopathy: Interim Results of a Prospective Study

INTRODUCTION: Ischemic cardiomyopathy remains a major contributor to chronic heart failure despite optimal guideline-directed medical therapy (GDMT). HEAT HF (HBOT and EECP as Adjuvant Therapy in Heart Failure) is the first prospective study to investigate the effect of Enhanced External Counterpulsation (EECP) with adjunctive Hyperbaric Oxygen Therapy (HBOT) on enhancing cardiac function and improving clinical outcomes in patients with ischemic cardiomyopathy. METHODS: This prospective interventional study was conducted on 100 adult patients with ischemic cardiomyopathy [left ventricular ejection fraction (LVEF) ≤50%] who had undergone EECP therapy with HBOT. Data on LVEF, global longitudinal strain (GLS), NYHA class, 6-minute walk test (6MWT), NT-proBNP, serum creatinine, and heart failure-related hospitalizations were collected pre- and post-intervention. This study is an ongoing clinical trial registered with the Clinical Trials Registry - India (CTRI/2024/11/076912), registered on November 18, 2024. This analysis represents interim results at 6-month follow-up. RESULTS: There were 88% males, with a mean age of 61.5 ± 10.7 years. LVEF significantly improved from 34.17 ± 7.0 to 41.43 ± 7.0% (p<0.001). 6MWT distance increased from 243.7 ± 94.4 to 367.4 ± 72.5 m (p<0.001), and NYHA class improved from III/IV to mainly I (p<0.001). GLS, NT-proBNP, and heart failure admissions also showed significant improvements (p < 0.001). LDL levels slightly decreased (p=0.046), while serum urea and creatinine remained unchanged. Patients on more GDMT agents showed better EF improvements, suggesting a synergistic effect. CONCLUSION: EECP, combined with HBOT and optimal GDMT, significantly improves cardiac function, exercise capacity, symptom burden, and biochemical markers in ischemic cardiomyopathy. This non-invasive approach may offer a promising adjunct to standard heart failure management.

Authors

Institutions

Publication Details

Journal
Journal of Cardiac Failure
Published
2026-05-01
DOI
https://doi.org/10.1016/j.cardfail.2026.04.020
Primary Topic
Pain Management and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combined Enhanced External Counterpulsation and Hyperbaric Oxygen Therapy in Ischemic Cardiomyopathy: Interim Results of a Prospective Study

Sama Akber, Dr Kanmani Srinivasan, Dr. Susheelkumar Alfred, Amir Ali et al.
Journal of Cardiac Failure
Pain Management and Treatment
article

Combined Enhanced External Counterpulsation and Hyperbaric Oxygen Therapy in Ischemic Cardiomyopathy: Interim Results of a Prospective Study

Sama Akber, Dr Kanmani Srinivasan, Dr. Susheelkumar Alfred, Amir Ali, Dr. Ganesan Ganavelu, Dr. D Prabhakaran, Dr. Ramanathan Muthiaya, Dr. Naveen Kishore Baskar, Dr. Natrajan Sivakadaksham
article en

Abstract

INTRODUCTION: Ischemic cardiomyopathy remains a major contributor to chronic heart failure despite optimal guideline-directed medical therapy (GDMT). HEAT HF (HBOT and EECP as Adjuvant Therapy in Heart Failure) is the first prospective study to investigate the effect of Enhanced External Counterpulsation (EECP) with adjunctive Hyperbaric Oxygen Therapy (HBOT) on enhancing cardiac function and improving clinical outcomes in patients with ischemic cardiomyopathy. METHODS: This prospective interventional study was conducted on 100 adult patients with ischemic cardiomyopathy [left ventricular ejection fraction (LVEF) ≤50%] who had undergone EECP therapy with HBOT. Data on LVEF, global longitudinal strain (GLS), NYHA class, 6-minute walk test (6MWT), NT-proBNP, serum creatinine, and heart failure-related hospitalizations were collected pre- and post-intervention. This study is an ongoing clinical trial registered with the Clinical Trials Registry - India (CTRI/2024/11/076912), registered on November 18, 2024. This analysis represents interim results at 6-month follow-up. RESULTS: There were 88% males, with a mean age of 61.5 ± 10.7 years. LVEF significantly improved from 34.17 ± 7.0 to 41.43 ± 7.0% (p<0.001). 6MWT distance increased from 243.7 ± 94.4 to 367.4 ± 72.5 m (p<0.001), and NYHA class improved from III/IV to mainly I (p<0.001). GLS, NT-proBNP, and heart failure admissions also showed significant improvements (p < 0.001). LDL levels slightly decreased (p=0.046), while serum urea and creatinine remained unchanged. Patients on more GDMT agents showed better EF improvements, suggesting a synergistic effect. CONCLUSION: EECP, combined with HBOT and optimal GDMT, significantly improves cardiac function, exercise capacity, symptom burden, and biochemical markers in ischemic cardiomyopathy. This non-invasive approach may offer a promising adjunct to standard heart failure management.

Journal of Cardiac Failure
Apollo Hospitals (IN), Cancer Institute (WIA) (IN), Sir Ivan Stedeford Hospital (IN), Samvedna Hospital (IN), Muthu Hospital (IN), National Institute of Pharmaceutical Education and Research (IN), Bridge Pharma (United States) (US), Suyash Hospital (IN)
Good health and well-being
Openalex Percentile: Top 7%
Pain Management and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.